IP Library Assignment 061601/0001
Patent Assignment
Reel/Frame 061601/0001

Security Interest

Recorded: 2022-10-31 Pages: 12
Assignor
PHASEBIO PHARMACEUTICALS, INC.
Executed: 2022-10-28
Assignee
JMB CAPITAL PARTNERS LENDING, LLC
205 SOUTH MARTEL AVENUE, LOS ANGELES, CALIFORNIA, 90036
Covered Properties (30)
Modified Vasoactive Intestinal Peptides
Application: 15/621,320 →
Publication: US 2018/0008677
Elp Fusion Proteins Comprising Parathyroid Hormone for Controlled and Sustained Release
Application: 17/633,369 →
Publication: US 2022/0289812
Formulations of Active Agents for Sustained Release
Application: 14/099,590 →
Publication: US 2014/0171370
Elp Fusion Proteins for Controlled and Sustained Release
Application: 16/099,261 →
Publication: US 2019/0218274
Elp Fusion Proteins Comprising Parathyroid Hormone for Controlled and Sustained Release
Application: 62/884,792 →
Metalloenzyme Inhibitor Compounds
Application: 17/421,567 →
Publication: US 2022/0081420
Pharmacokinetic & Pharmacodynamic Model for Determining Effective Dose of Anti-Ticagrelor Antibody
Application: 17/739,491 →
Publication: US 2023/0192895
Metalloenzyme Inhibitor Compounds
Application: 17/350,726 →
Publication: US 2021/0322409
Methods and Compositions for Treating Cystic Fibrosis
Application: 17/365,443 →
Publication: US 2022/0023390
Metalloenzyme Inhibitor Compounds
Application: 17/462,909 →
Publication: US 2022/0009907
Methods and Compositions for Treating Muscle Disease and Disorders
Application: 17/583,883 →
Publication: US 2022/0288170
Elp Fusion Proteins for Controlled and Sustained Release
Application: 16/939,624 →
Publication: US 2020/0353091
Methods of Reversing Ticagrelor Activity
Application: 17/278,075 →
Publication: US 2021/0347915
Vasoactive Intestinal Peptide Fusion Proteins for the Treatment of Covid-19
Application: 63/032,244 →
Pharmacokinetic & Pharmacodynamic Model for Determining Effective Dose of Anti-Ticagrelor Antibody
Application: 63/186,515 →
Modified Vasoactive Intestinal Peptides
Patent: 9,029,505 →
Application: 12/857,103 →
Publication: US 2011/0178017
Modified Vasoactive Intestinal Peptides
Patent: 9,700,598 →
Application: 14/681,597 →
Publication: US 2016/0220642
Multimeric Elp Fusion Constructs
Patent: 7,709,227 →
Application: 11/620,034 →
Publication: US 2008/0032400
Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension
Patent: 9,561,262 →
Application: 14/124,612 →
Publication: US 2015/0111829
Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension
Application: 15/276,151 →
Publication: US 2017/0072021
A Method for Administering a Sustained Release Formulation
Patent: 9,919,032 →
Application: 15/355,386 →
Publication: US 2017/0136092
Methods and Compositions for Treating Cystic Fibrosis
Application: 15/308,626 →
Publication: US 2017/0182130
Elp Fusion Proteins for Controlled and Sustained Release
Application: 15/527,985 →
Publication: US 2019/0015523
Methods and Compositions for Treating Muscle Disease and Disorders
Application: 15/546,037 →
Publication: US 2018/0333467
Metalloenzyme Inhibitor Compounds
Application: 15/858,015 →
Publication: US 2018/0186773
Metalloenzyme Inhibitor Compounds
Application: 15/857,950 →
Publication: US 2018/0185362
Metalloenzyme Inhibitor Compounds
Application: 16/124,846 →
Publication: US 2019/0008861
Metalloenzyme Inhibitor Compounds
Application: 16/746,098 →
Publication: US 2020/0392112
Therapeutic Agents Comprising a Bmp-9 Peptide and Eleastin-Like Peptides
Application: 16/720,970 →
Publication: US 2020/0282022
Methods and Compositions for Treating Muscle Disease and Disorders
Application: 16/907,759 →
Publication: US 2021/0069299
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jan 23, 2007
From: DAGHER, SUZANNE
To: PHASE BIOSCIENCE, INC.
Reel/Frame 018802/0961 →
Change of Name Mar 26, 2010
From: PHASE BIOSCIENCE, INC.
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 024143/0049 →
Assignment of Assignor's Interest Jun 30, 2011
From: SADEGHI, HOMAYOUN; TURNER, ANDREW; DAGHER, SUZANNE
To: PHASBIO PHARMACEUTICALS, INC.
Reel/Frame 026530/0468 →
Assignment of Assignor's Interest Mar 10, 2014
From: ARNOLD, SUSAN; PRIOR, CHRISTOPHER
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 032388/0075 →
Assignment of Assignor's Interest Mar 10, 2014
From: GEORGOPOULOS, LYNNE M.; ARNOLD, SUSAN
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 032388/0090 →
Assignment of Assignor's Interest Nov 23, 2015
From: SADEGHI, HOMAYOUN; DAGHER, SUZANNE; TURNER, ANDREW
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 037117/0277 →
Assignment of Assignor's Interest Feb 1, 2018
From: ARNOLD, SUSAN; PRIOR, CHRISTOPHER; GEORGOPOULOS, LYNNE
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 044795/0680 →
Assignment of Assignor's Interest Apr 4, 2018
From: ARNOLD, SUSAN; BALLANCE, DAVID JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 045434/0757 →
Assignment of Assignor's Interest Jun 15, 2018
From: GEORGOPOULOS, LYNNE M.; ARNOLD, SUSAN
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 046099/0507 →
Assignment of Assignor's Interest Jun 15, 2018
From: SADEGHI, HOMAYOUN; DAGHER, SUZANNE; TURNER, ANDREW
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 046097/0317 →
Assignment of Assignor's Interest Apr 4, 2019
From: JOWETT, JAMES; BALLANCE, DAVID JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 048796/0907 →
Assignment of Assignor's Interest Sep 26, 2019
From: BALLANCE, DAVID JAMES; JOWETT, JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 050504/0051 →
Security Interest Apr 21, 2020
From: PHASEBIO PHARMACEUTICALS, INC.
To: SILICON VALLEY BANK, AS AGENT
Reel/Frame 052456/0343 →
Assignment of Assignor's Interest Oct 29, 2020
From: LEE, JOHN; PAUL, SUMITA
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 054206/0524 →
Assignment of Assignor's Interest Oct 29, 2020
From: JOWETT, JAMES; BALLANCE, DAVID JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 054206/0431 →
Assignment of Assignor's Interest Oct 29, 2020
From: JOWETT, JAMES; BALLANCE, DAVID JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 054206/0385 →
Patent and Trademark Security Agreement Nov 12, 2020
From: PHASEBIO PHARMACEUTICALS, INC.
To: SFJ PHARMACEUTICALS X, LTD.
Reel/Frame 054401/0188 →
Security Interest Jun 1, 2021
From: PHASEBIO PHARMACEUTICALS, INC.
To: SILICON VALLEY BANK
Reel/Frame 056405/0575 →
Assignment of Assignor's Interest Jul 8, 2021
From: SELENITY THERAPEUTICS (BERMUDA), LTD.
To: PHASE BIO PHARMACEUTICALS, INC.
Reel/Frame 056794/0957 →
Assignment of Assignor's Interest Jul 8, 2021
From: SPARKS, STEVEN; YATES, CHRISTOPHER M.
To: SELENITY THERAPEUTICS, LLC
Reel/Frame 056794/0876 →
Assignment of Assignor's Interest Jul 8, 2021
From: SELENITY THERAPEUTICS, LLC
To: SELENITY THERAPEUTICS (BERMUDA), LTD.
Reel/Frame 056794/0905 →
Assignment of Assignor's Interest Aug 10, 2021
From: LEE, JOHN; BALLANCE, DAVID JAMES
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 057130/0283 →
Assignment of Assignor's Interest May 5, 2022
From: LEE, JOHN
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 059821/0980 →
Assignment of Assignor's Interest Aug 30, 2022
From: LEE, JOHN
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 060941/0887 →
Assignment of Intellectual Property Security Agreement Oct 4, 2022
From: SILICON VALLEY BANK
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 061606/0035 →